Literature DB >> 14675260

Pathogenesis and management of alcoholic hepatitis.

Paul S Haber1, Ross Warner, Devanshi Seth, Mark D Gorrell, Geoffrey W McCaughan.   

Abstract

Alcoholic hepatitis is a potentially life-threatening complication of alcoholic abuse, typically presenting with symptoms and signs of hepatitis in the presence of an alcohol use disorder. The definitive diagnosis requires liver biopsy, but this is not generally required. The pathogenesis is uncertain, but relevant factors include metabolism of alcohol to toxic products, oxidant stress, acetaldehyde adducts, the action of endotoxin on Kupffer cells, and impaired hepatic regeneration. Mild alcoholic hepatitis recovers with abstinence and the long-term prognosis is determined by the underlying disorder of alcohol use. Severe alcoholic hepatitis is recognized by a Maddrey discriminant function >32 and is associated with a short-term mortality rate of almost 50%. Primary therapy is abstinence from alcohol and supportive care. Corticosteroids have been shown to be beneficial in a subset of severely ill patients with concomitant hepatic encephalopathy, but their use remains controversial. Pentoxifylline has been shown in one study to improve short-term survival rates. Other pharmacological interventions, including colchicine, propylthiouracil, calcium channel antagonists, and insulin with glucagon infusions, have not been proven to be beneficial. Nutritional supplementation with available high-calorie, high-protein diets is beneficial, but does not improve mortality. Orthotopic liver transplantation is not indicated for patients presenting with alcoholic hepatitis who have been drinking until the time of admission, but may be considered in those who achieve stable abstinence if liver function fails to recover.

Entities:  

Mesh:

Year:  2003        PMID: 14675260     DOI: 10.1046/j.1440-1746.2003.03217.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  19 in total

1.  Challenge for doctors and policy makers.

Authors:  Paul Haber
Journal:  BMJ       Date:  2006-02-04

Review 2.  Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials.

Authors:  Chao-Hui Yu; Cheng-Fu Xu; Hua Ye; Lan Li; You-Ming Li
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

3.  Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases.

Authors:  Anastasios E Germenis; Efthalia E Yiannaki; Kalliopi Zachou; Violeta Roka; Sotirios Barbanis; Christos Liaskos; Kalliopi Adam; Andreas N Kapsoritakis; Spyros Potamianos; Georgios N Dalekos
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

4.  Risk factors for liver disease and associated knowledge and practices among Mexican adults in the US and Mexico.

Authors:  Yvonne N Flores; Cathy M Lang; Jorge Salmerón; Roshan Bastani
Journal:  J Community Health       Date:  2012-04

5.  Alcoholic versus nonalcoholic cirrhosis in a randomized controlled trial of emergency therapy of bleeding varices.

Authors:  Marshall J Orloff; Jon I Isenberg; Henry O Wheeler; Kevin S Haynes; Horacio Jinich-Brook; Roderick Rapier; Florin Vaida; Robert J Hye; Susan L Orloff
Journal:  J Surg Res       Date:  2010-12-03       Impact factor: 2.192

6.  Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: a cross-sectional study.

Authors:  Noreen Islam; Yvonne N Flores; Paula Ramirez; Roshan Bastani; Jorge Salmerón
Journal:  Int J Public Health       Date:  2013-10-06       Impact factor: 3.380

Review 7.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

8.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

9.  Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans.

Authors:  Youngmi Jung; Kevin D Brown; Rafal P Witek; Alessia Omenetti; Liu Yang; Margon Vandongen; Richard J Milton; Ian N Hines; Richard A Rippe; Laurent Spahr; Laura Rubbia-Brandt; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

10.  Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.

Authors:  Binay Krishna De; Subhabrata Gangopadhyay; Deep Dutta; Sumanta Das Baksi; Adyapad Pani; Pramit Ghosh
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.